While targeted therapies are available for molecularly defined advanced NSCLC patients, such as those with EGFR mutations or ALK rearrangements, a significant proportion of NSCLC cases lacking such genetic mutations renders these therapies ineffective. This evidence concerns the gene ALK and non-small cell lung carcinoma.